GlassScriptPhysician profile
Karla N Vital
NPI 1831258284
$11,563.70
in general payments reported to CMS, 2019-2025
25 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $246 · 2021: $8,032 · 2022: $726 · 2023: $1,528 · 2024: $200 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $8,626.44 | 2020-2023 | Benlysta |
| Novo Nordisk INC | $1,046.92 | 2019-2025 | Ozempic, Wegovy |
| Csl Behring | $270.30 | 2020-2025 | Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $159.83 | 2022-2023 | Cuvitru |
| Octapharma USA, INC. | $158.38 | 2020-2021 | |
| Kaleo, INC. | $141.44 | 2019-2023 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $118.33 | 2022-2025 | Dupixent |
| Baxter Healthcare | $116.88 | 2019 | |
| Lilly USA, LLC | $108.61 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Genzyme Corporation | $107.47 | 2020-2024 | |
| Optinose US, INC. | $97.66 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.89 | 2023 | |
| Pharming Healthcare, INC. | $89.01 | 2019-2025 | Ruconest |
| Horizon Therapeutics Plc | $79.06 | 2019 | |
| Grifols USA, LLC | $65.45 | 2021-2023 | Xembify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $51.14 | 2019-2022 | |
| Leo Pharma INC. | $50.13 | 2022 | |
| Shire North American Group INC | $40.04 | 2019 | |
| Opko Pharmaceuticals, LLC | $35.99 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $20.15 | 2025 | Dawnzera |
| Azurity Pharmaceuticals, INC. | $18.66 | 2025 | Alvesco |
| Eyevance Pharmaceuticals LLC | $18.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2022 | |
| Phadia US INC. | $15.72 | 2024 | Immunocap |
| Endo Pharmaceuticals INC. | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Vital listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.